Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT

Overview

Journal Front Pharmacol

Date 2016 Apr 12

PMID 27065872

Citations 10

Authors

Lieven D Declercq

Rik Vandenberghe

Koen Van Laere

Alfons Verbruggen

Guy Bormans

Affiliations

Soon will be listed here.

Abstract

Clinical trials aiming to develop disease-altering drugs for Alzheimer's disease (AD), a neurodegenerative disorder with devastating consequences, are failing at an alarming rate. Poorly defined inclusion-and outcome criteria, due to a limited amount of objective biomarkers, is one of the major concerns. Non-invasive molecular imaging techniques, positron emission tomography and single photon emission (computed) tomography (PET and SPE(C)T), allow visualization and quantification of a wide variety of (patho)physiological processes and allow early (differential) diagnosis in many disorders. PET and SPECT have the ability to provide biomarkers that permit spatial assessment of pathophysiological molecular changes and therefore objectively evaluate and follow up therapeutic response, especially in the brain. A number of specific PET/SPECT biomarkers used in support of emerging clinical therapies in AD are discussed in this review.

Citing Articles

Acyl Amidines by Pd-Catalyzed Aminocarbonylation: One-Pot Cyclizations and C Labeling.

Rydfjord J, Roslin S, Roy T, Abbas A, Stevens M, Odell L J Org Chem. 2022; 88(8):5078-5089.

PMID: 36520948 PMC: 10127271. DOI: 10.1021/acs.joc.2c02115.

Impact of Donepezil on Brain Glucose Metabolism Assessed Using [F]2-Fluoro-2-deoxy-D-Glucose Positron Emission Tomography Imaging in a Mouse Model of Alzheimer's Disease Induced by Intracerebroventricular Injection of Amyloid-Beta Peptide.

Hugon G, Goutal S, Sarazin M, Bottlaender M, Caille F, Droguerre M Front Neurosci. 2022; 16:835577.

PMID: 35281502 PMC: 8916213. DOI: 10.3389/fnins.2022.835577.

Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor.

Allen S, Liu X, Jiang J, Liao Y, Chang C, Nel A Biomaterials. 2021; 269:120635.

PMID: 33422940 PMC: 7870571. DOI: 10.1016/j.biomaterials.2020.120635.

Potential Role of Phenolic Extracts of in Managing Oxidative Stress and Alzheimer's Disease.

Hanafy D, Burrows G, Prenzler P, Hill R Antioxidants (Basel). 2020; 9(7).

PMID: 32709074 PMC: 7402171. DOI: 10.3390/antiox9070631.

Dementia spectrum disorders: lessons learnt from decades with PET research.

Wilson H, Pagano G, Politis M J Neural Transm (Vienna). 2019; 126(3):233-251.

PMID: 30762136 PMC: 6449308. DOI: 10.1007/s00702-019-01975-4.

References

Chua S, Kassiou M, Ittner L . The translocator protein as a drug target in Alzheimer's disease. Expert Rev Neurother. 2014; 14(4):439-48. DOI: 10.1586/14737175.2014.896201. View

Bancher C, Jellinger K, Lassmann H, Fischer P, Leblhuber F . Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia. Eur Arch Psychiatry Clin Neurosci. 1996; 246(3):137-46. DOI: 10.1007/BF02189115. View

Ishiki A, Okamura N, Furukawa K, Furumoto S, Harada R, Tomita N . Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography. PLoS One. 2015; 10(10):e0140311. PMC: 4604169. DOI: 10.1371/journal.pone.0140311. View

Coyle J, Price D, DeLong M . Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1983; 219(4589):1184-90. DOI: 10.1126/science.6338589. View

Frolich L, Ashwood T, Nilsson J, Eckerwall G . Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study. J Alzheimers Dis. 2011; 24(2):363-74. DOI: 10.3233/JAD-2011-101554. View

Kemppainen N, Laine M, Laakso M, Kaasinen V, Nagren K, Vahlberg T . Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci. 2003; 18(1):149-54. DOI: 10.1046/j.1460-9568.2003.02716.x. View

Covington J . Alleviating agitation, apprehension, and related symptoms in geriatric patients: A double-blind comparison of a phenothiazine and a benzodiazepien. South Med J. 1975; 68(6):719-24. DOI: 10.1097/00007611-197506000-00015. View

Jurgensen S, Ferreira S . Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer's disease. J Mol Neurosci. 2009; 40(1-2):221-9. DOI: 10.1007/s12031-009-9237-0. View

Wu T, Chen C, Jinn T . Alzheimer's disease: aging, insomnia and epigenetics. Taiwan J Obstet Gynecol. 2011; 49(4):468-72. DOI: 10.1016/S1028-4559(10)60099-X. View

10.

Chebib M, Johnston G . The 'ABC' of GABA receptors: a brief review. Clin Exp Pharmacol Physiol. 1999; 26(11):937-40. DOI: 10.1046/j.1440-1681.1999.03151.x. View

11.

Puzzo D, Arancio O . Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?. J Alzheimers Dis. 2012; 33 Suppl 1:S111-20. PMC: 3696497. DOI: 10.3233/JAD-2012-129033. View

12.

Nordberg A, Lundqvist H, Hartvig P, Andersson J, Johansson M, Langstrom B . Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement Geriatr Cogn Disord. 1997; 8(2):78-84. DOI: 10.1159/000106611. View

13.

Tyrrell P, Sawle G, Ibanez V, Bloomfield P, Leenders K, Frackowiak R . Clinical and positron emission tomographic studies in the 'extrapyramidal syndrome' of dementia of the Alzheimer type. Arch Neurol. 1990; 47(12):1318-23. DOI: 10.1001/archneur.1990.00530120062011. View

14.

Lanctot K, Herrmann N, Black S, Ryan M, Rothenburg L, Liu B . Apathy associated with Alzheimer disease: use of dextroamphetamine challenge. Am J Geriatr Psychiatry. 2008; 16(7):551-7. DOI: 10.1097/JGP.0b013e318170a6d1. View

15.

Frankle W, Cho R, Narendran R, Mason N, Vora S, Litschge M . Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects. Neuropsychopharmacology. 2008; 34(3):624-33. PMC: 2754778. DOI: 10.1038/npp.2008.104. View

16.

Bonner T, Buckley N, Young A, Brann M . Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987; 237(4814):527-32. DOI: 10.1126/science.3037705. View

17.

Dewar D, Graham D, McCulloch J . 5 HT2 receptors in dementia of Alzheimer type: a quantitative autoradiographic study of frontal cortex and hippocampus. J Neural Transm Park Dis Dement Sect. 1990; 2(2):129-37. DOI: 10.1007/BF02260900. View

18.

Paterson L, Kornum B, Nutt D, Pike V, Knudsen G . 5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev. 2011; 33(1):54-111. PMC: 4188513. DOI: 10.1002/med.20245. View

19.

Palacios J, BOLLIGER G, Closse A, Enz A, Gmelin G, Malanowski J . The pharmacological assessment of RS 86 (2-ethyl-8-methyl-2,8-diazaspiro-[4,5]-decan-1,3-dion hydrobromide). A potent, specific muscarinic acetylcholine receptor agonist. Eur J Pharmacol. 1986; 125(1):45-62. DOI: 10.1016/0014-2999(86)90082-8. View

20.

Polidori M, Nelles G . Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease - challenges and perspectives. Curr Pharm Des. 2013; 20(18):3083-92. DOI: 10.2174/13816128113196660706. View